Suppr超能文献

炎症微环境中心脏修复中的干细胞

Stem cells in cardiac repair in an inflammatory microenvironment.

作者信息

Rameshwar P, Qiu H, Vatner S F

机构信息

Department of Medicine, New Jersey Medical School-UMDNJ, Newark, NJ, USA.

出版信息

Minerva Cardioangiol. 2010 Feb;58(1):127-46.

Abstract

Despite advances in clinical interventions, drug therapy and preventative strategies for cardiovascular disease, heart disease remains the number one cause of death in the United States. A major cause of heart failure leading to death is myocardial ischemic disease. Terminal heart failure can be salvaged in some cases by cardiac transplants, but this therapeutic approach is limited by lack of supply, high cost, and problems with immunosuppression. An attractive alternative approach proposed over the last 1-2 decades is the replacement of myocardium at the level of the myocyte, which has focused on stem cell therapy. This form of therapy has been successful for hematopoietic replacement. Similar therapy has been proposed to treat hearts ravaged by ischemic necrosis and apoptosis. However, the experimental studies have not been effectively translated to patients with myocardial infarction or heart failure. This review discusses the current literature and points out key studies that are required for future directions, focusing on key roles for microenvironmental factors, such as cytokines, in stem cells responses when placed at sites of cardiac injuries. In the case of mesenchymal stem cells (MSCs), they exert both immune- enhancer and -suppressor functions, which are referred to as immune plasticity. This type of immune properties by MSCs is significant to therapeutic outcomes. Thus, the plasticity of MSCs, with regards to immune responses, has to be considered carefully in tissue repair and replacement and in gene delivery systems. The route by which cytokines are delivered as adjuvant to cell therapy, or as methods to mobilize stem cells, will show varied results, depending on the degree of injury, underlying clinical disorders and other diverse parameters, such as ethnicity, age and genomic profile. In addition to MSCs, roles exist for other stem cells, such as those from placenta, cord blood, hematopoietic stem/progenitor cells and cardiac stem cells.

摘要

尽管在心血管疾病的临床干预、药物治疗和预防策略方面取得了进展,但心脏病仍然是美国的头号死因。导致死亡的心力衰竭的一个主要原因是心肌缺血性疾病。在某些情况下,终末期心力衰竭可以通过心脏移植挽救,但这种治疗方法受到供体短缺、成本高昂和免疫抑制问题的限制。在过去的10到20年里,提出了一种有吸引力的替代方法,即在心肌细胞水平上替换心肌,这一方法主要集中在干细胞治疗上。这种治疗形式在造血细胞替代方面已经取得成功。人们也提出了类似的疗法来治疗因缺血性坏死和细胞凋亡而受损的心脏。然而,实验研究尚未有效地转化应用于心肌梗死或心力衰竭患者。本综述讨论了当前的文献,并指出了未来研究方向所需的关键研究,重点关注微环境因素(如细胞因子)在干细胞置于心脏损伤部位时的反应中的关键作用。就间充质干细胞(MSC)而言,它们具有免疫增强和免疫抑制功能,这被称为免疫可塑性。MSC的这种免疫特性对治疗结果具有重要意义。因此,在组织修复和替代以及基因递送系统中,必须仔细考虑MSC在免疫反应方面的可塑性。作为细胞治疗佐剂或动员干细胞的方法,细胞因子的递送途径将根据损伤程度、潜在临床疾病以及其他各种参数(如种族、年龄和基因组特征)而产生不同的结果。除了MSC外,其他干细胞也发挥作用,如来自胎盘、脐带血的干细胞、造血干/祖细胞和心脏干细胞。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验